A detailed history of Rhumbline Advisers transactions in Axogen, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 56,711 shares of AXGN stock, worth $756,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,711
Previous 58,157 2.49%
Holding current value
$756,524
Previous $421,000 88.84%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.52 - $14.69 $10,873 - $21,241
-1,446 Reduced 2.49%
56,711 $795,000
Q2 2024

Aug 01, 2024

BUY
$5.67 - $8.06 $19,164 - $27,242
3,380 Added 6.17%
58,157 $421,000
Q1 2024

May 09, 2024

BUY
$6.63 - $10.69 $10,939 - $17,638
1,650 Added 3.11%
54,777 $442,000
Q4 2023

Feb 08, 2024

SELL
$3.61 - $7.76 $5,700 - $12,253
-1,579 Reduced 2.89%
53,127 $362,000
Q3 2023

Nov 09, 2023

BUY
$4.68 - $9.26 $1,530 - $3,028
327 Added 0.6%
54,706 $273,000
Q2 2023

Aug 08, 2023

BUY
$8.5 - $10.38 $12,979 - $15,850
1,527 Added 2.89%
54,379 $496,000
Q1 2023

May 11, 2023

SELL
$7.53 - $10.95 $4,984 - $7,248
-662 Reduced 1.24%
52,852 $499,000
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $11,460 - $15,891
1,214 Added 2.32%
53,514 $534,000
Q3 2022

Nov 10, 2022

BUY
$8.14 - $12.25 $30,451 - $45,827
3,741 Added 7.7%
52,300 $623,000
Q2 2022

Aug 11, 2022

BUY
$6.99 - $10.0 $50,922 - $72,850
7,285 Added 17.65%
48,559 $398,000
Q1 2022

May 12, 2022

BUY
$7.26 - $10.7 $2,998 - $4,419
413 Added 1.01%
41,274 $328,000
Q4 2021

Feb 10, 2022

SELL
$8.8 - $16.0 $12,900 - $23,456
-1,466 Reduced 3.46%
40,861 $383,000
Q3 2021

Nov 12, 2021

BUY
$15.23 - $21.72 $26,088 - $37,206
1,713 Added 4.22%
42,327 $669,000
Q2 2021

Aug 05, 2021

SELL
$17.8 - $23.5 $50,712 - $66,951
-2,849 Reduced 6.56%
40,614 $878,000
Q1 2021

May 06, 2021

SELL
$17.18 - $22.6 $43,121 - $56,726
-2,510 Reduced 5.46%
43,463 $881,000
Q4 2020

Feb 10, 2021

BUY
$11.5 - $17.96 $25,875 - $40,410
2,250 Added 5.15%
45,973 $823,000
Q3 2020

Nov 12, 2020

SELL
$10.62 - $13.12 $66,428 - $82,065
-6,255 Reduced 12.52%
43,723 $508,000
Q2 2020

Aug 13, 2020

BUY
$7.35 - $10.81 $28,319 - $41,650
3,853 Added 8.35%
49,978 $462,000
Q1 2020

May 06, 2020

BUY
$8.38 - $17.34 $8,631 - $17,860
1,030 Added 2.28%
46,125 $480,000
Q4 2019

Feb 05, 2020

BUY
$11.18 - $18.6 $2,817 - $4,687
252 Added 0.56%
45,095 $807,000
Q3 2019

Oct 23, 2019

SELL
$12.09 - $20.46 $3,445 - $5,831
-285 Reduced 0.63%
44,843 $560,000
Q2 2019

Aug 14, 2019

SELL
$18.5 - $25.47 $18,500 - $25,470
-1,000 Reduced 2.17%
45,128 $894,000
Q1 2019

May 01, 2019

SELL
$14.62 - $22.13 $22,105 - $33,460
-1,512 Reduced 3.17%
46,128 $971,000
Q4 2018

Jan 31, 2019

BUY
$17.09 - $38.25 $295,810 - $662,069
17,309 Added 57.07%
47,640 $973,000
Q3 2018

Nov 07, 2018

SELL
$34.05 - $55.9 $73,275 - $120,296
-2,152 Reduced 6.63%
30,331 $1.12 Million
Q2 2018

Aug 06, 2018

BUY
$36.15 - $52.5 $251,061 - $364,612
6,945 Added 27.19%
32,483 $1.63 Million
Q1 2018

May 02, 2018

BUY
$24.4 - $40.25 $32,573 - $53,733
1,335 Added 5.52%
25,538 $932,000
Q4 2017

Feb 09, 2018

SELL
$18.5 - $28.6 $90,779 - $140,340
-4,907 Reduced 16.86%
24,203 $685,000
Q3 2017

Nov 06, 2017

BUY
$14.65 - $19.35 $426,461 - $563,278
29,110
29,110 $563,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $564M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.